Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Dentsply Sirona (XRAY)

Dentsply Sirona names Daniel Scavilla CEO effective Aug. 1; reaffirms 2025 outlook

Neutral Impact 4 of 5 leadership Written later

Dentsply Sirona said its board appointed Daniel Scavilla, a director since February 2025 and former Globus Medical CEO, as president and chief executive officer effective August 1, 2025, succeeding Simon Campion, who leaves on July 31, 2025. The company also issued preliminary second quarter 2025 results and reaffirmed its 2025 outlook, which gives shareholders a clearer view of the leadership transition and near-term results, though the filing gives no prior-year comparison.

Key points

  • Preliminary second quarter 2025 net sales are expected to be approximately $935 million, with adjusted EPS between $0.50 and $0.52.
  • The company reaffirmed its 2025 outlook from its May 8, 2025 earnings release and plans to report second quarter results on August 7, 2025.
  • Scavilla will receive an annual base salary of $1,030,000 and a target bonus of 135% of base salary; Campion resigned from the board effective July 20, 2025, reducing its size from eleven to ten members.

The filing

CompanyDentsply Sirona (XRAY)
Form8-K, current report
Filed with the SECJul 21, 2025, 8:33 AM ET
Accession number0000818479-25-000137

Items reported: 2.02 Results of Operations5.02 Director / Officer Change7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:55 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 21, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.